Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis

Arthritis and Rheumatism

Volumn 63, Issue 1, 2011, Pages 84-95

  Arce, Frederick ^a   Breckpot, Karine ^a,b   Stephenson, Holly ^a   Karwacz, Katarzyna ^a   Ehrenstein, Michael R ^a   Collins, Mary ^a   Escors, David ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL PROLIFERATION; DENDRITIC CELL; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; INFLAMMATION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; VACCINATION;

ANALYSIS OF VARIANCE; ANIMALS; ARTHRITIS, EXPERIMENTAL; BUTADIENES; CELL DIFFERENTIATION; CELL LINE; CELLS, CULTURED; DENDRITIC CELLS; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; FLOW CYTOMETRY; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; MICE; NITRILES; T-LYMPHOCYTES, REGULATORY;

EID: 78650796666     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30099     Document Type: Article

References (41)

1. Flores-Borja F, Mauri C, Ehrenstein MR,. Restoring the balance: harnessing regulatory T cells for therapy in rheumatoid arthritis. Eur J Immunol 2008; 38: 934-7.
2. Imperato AK, Bingham CO III, Abramson SB,. Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22: S108-14.
3. Wright GP, Notley CA, Xue SA, Bendle GM, Holler A, Schumacher TN, et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A 2009; 106: 19078-83.
4. Riley JL, June CH, Blazar BR,. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009; 30: 656-65.
5. Rutella S, Danese S, Leone G,. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006; 108: 1435-40.
6. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213-22.
7. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G,. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001; 166: 4312-8.
8. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N,. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233-8.
9. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769-79.
10. + T cell tolerance. J Exp Med 2002; 196: 1627-38.
11. Manicassamy S, Ravindran R, Deng J, Oluoch H, Denning TL, Kasturi SP, et al. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat Med 2009; 15: 401-9.
12. Loscher CE, Draper E, Leavy O, Kelleher D, Mills KH, Roche HM,. Conjugated linoleic acid suppresses NF-ÎB activation and IL-12 production in dendritic cells through ERK-mediated IL-10 induction. J Immunol 2005; 175: 4990-8.
13. Ilarregui JM, Croci DO, Bianco GA, Toscano MA, Salatino M, Vermeulen ME, et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 2009; 10: 981-91.
14. Belladonna ML, Orabona C, Grohmann U, Puccetti P,. TGF-β and kynurenines as the key to infectious tolerance. Trends Mol Med 2009; 15: 41-9.
15. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29: 565-77.
16. mapk are involved in IL-10-mediated selective repression of TNF-α-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J Immunol 1999; 162: 3865-72.
17. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S,. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70: 68-77.
18. Dillon S, Agrawal S, Banerjee K, Letterio J, Denning TL, Oswald-Richter K, et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest 2006; 116: 916-28.
19. Caparros E, Munoz P, Sierra-Filardi E, Serrano-Gomez D, Puig-Kroger A, Rodriguez-Fernandez JL, et al. DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood 2006; 107: 3950-8.
20. Jackson AM, Mulcahy LA, Zhu XW, O'Donnell D, Patel PM,. Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation. Int J Cancer 2008; 123: 623-32.
21. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC,. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006; 203: 1685-91.
22. Brereton CF, Sutton CE, Lalor SJ, Lavelle EC, Mills KH,. Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease. J Immunol 2009; 183: 1715-23.
23. Thiel MJ, Schaefer CJ, Lesch ME, Mobley JL, Dudley DT, Tecle H, et al. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. Arthritis Rheum 2007; 56: 3347-57.
24. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W,. Interleukin-10- deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-74.
25. Escors D, Lopes L, Lin R, Hiscott J, Akira S, Davis RJ, et al. Targeting dendritic cell signalling to regulate the response to immunisation. Blood 2008; 111: 3050-61.
26. Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, de Greef C, et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 2003; 5: 654-67.
27. Breckpot K, Aerts-Toegaert C, Heirman C, Peeters U, Beyaert R, Aerts JL, et al. Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J Immunol 2009; 182: 860-70.
28. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM,. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17: 3091-100.
29. Selden C, Mellor N, Rees M, Laurson J, Kirwan M, Escors D, et al. Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes. J Gene Med 2007; 9: 67-76.
30. + regulatory T cells. J Leukoc Biol 2007; 82: 93-105.
31. + T lymphocytes can produce gamma interferon without cytotoxicity. J Virol 2005; 79: 5568-76.
32. Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C, et al. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods 2002; 264: 135-51.
33. Escors D, Breckpot K,. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) 2010; 58: 107-19.
34. Breckpot K, Escors D, Arce F, Lopes L, Karwacz K, Van Lint S, et al. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol 2010; 84: 5627-36.
35. + T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006; 24: 643-56.
36. + regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A 2004; 101: 4572-7.
37. + regulatory T cells. Proc Natl Acad Sci U S A 2007; 104: 2821-6.
38. high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol 2007; 37: 3054-62.
39. Saraiva M, O'Garra A,. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10: 170-81.
40. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR,. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A 2008; 105: 19396-401.
41. Breckpot K, Escors D,. Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocr Metab Immune Disord Drug Targets 2009; 9: 328-43.